The longevity economy
The public case for longevity innovation begins with demographic change, chronic-disease burden and the need for better-supported healthy years. Commercial forecasts vary widely with category definitions and should be verified independently.
Demand signals
These signals come from public-health and population authorities. They establish context, but they do not prove demand for any specific MRD product.
Population ageing
WHO projects 1.4 billion people in this age group by 2030, increasing the need for products and systems that support function, independence and quality of life.
Source: WHOHealthspan gap
This comparison using WHO estimates helps explain why more healthy years, not lifespan alone, is the more useful innovation target.
Review the sourced comparisonChronic disease burden
The opportunity for responsible innovation sits alongside established priorities: prevention, movement, nutrition, sleep, clinical care and risk reduction.
Source: WHODesign imperative
Commercial diligence
A large category does not establish product-market fit. Qualified discussions should examine the evidence closest to the actual product and customer.
Who has the problem, who makes the decision and who pays?
What is the exact formula or device, stage, intended use and evidence package?
Which territories, channels, partners and claims are commercially and legally appropriate?
What are the manufacturing, quality, fulfilment, acquisition and support requirements?
MRD's position
MRD's current product focus, development platform and exploratory research require different partners, proof and timelines.
Review partnership fit